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Abstract Emerging evidence suggests that many meta-
static cancers arise from cells of the myeloid/macrophage
lineage regardless of the primary tissue of origin. A
myeloid origin of metastatic cancer stands apart from
origins involving clonal evolution or epithelial–mesenchy-
mal transitions. Evidence is reviewed demonstrating that
numerous human cancers express multiple properties of
macrophages including phagocytosis, fusogenicity, and
gene/protein expression. It is unlikely that the macrophage
properties expressed in metastatic cancers arise from
sporadic random mutations in epithelial cells, but rather
from damage to an already existing mesenchymal cell, e.g.,
a myeloid/macrophage-type cell. Such cells would naturally
embody the capacity to express the multiple behaviors of
metastatic cells. The view of metastasis as a myeloid/
macrophage disease will impact future cancer research and
anti-metastatic therapies.
Keywords Metastatic cancer.Myeloid/macrophage
lineage.Epithelial–mesenchymal transitions.Phagocytosis
1 Introduction
Cancer is a complex disease resulting in tumors composed
of multiple cell types with diverse biological characteristics
[1, 2]. Cells within the primary tumor can differ with
respect to origin, growth rate, karyotype, drug sensitivity,
and metastatic potential [2–4]. While each cell type within
the primary tumor contributes to the malignancy of the
disease, cells that acquire the abilities to invade and to
metastasize are responsible for the majority of cancer
related deaths [1, 5]. Despite the clinical importance of
metastasis, much remains unknown about the origin and
development of this disease.
Metastasis involves the spread of cancer cells from the
primary tumor to surrounding tissues and distant organs.
The metastatic cascade is a series of sequential and
interrelated steps to include cancer cell detachment from
the primary tumor, intravasation into the circulation,
evasion of immune attack, extravasation at a distant
capillary bed, and invasion and proliferation in distant
organs [6–10]. Metastatic cells also establish a microenvi-
ronment through the release of cytokines and growth
factors that facilitate angiogenesis and proliferation, result-
ing in macroscopic, malignant secondary tumors. In
addition, metastatic cells preferentially invade those organs
(lymph nodes, lung, liver, brain, bone, pleura, and
peritoneum) that promote tumor cell growth and survival
consistent with the “seed and soil” hypothesis [8, 11–14].
While the major steps of metastasis are well documented,
the process by which a metastatic cell arises from a
population of non-metastatic cells in a primary tumor is
largely unknown [15–17].
Several mechanisms have been advanced to account for
the origin of metastasis. It is widely thought that metastatic
cancer cells arise from pre-existing tumor cells that have
undergone additional genetic alterations during the later
stages of tumor progression, a process known as the clonal
origin of metastasis [1, 9, 18–20]. The epithelial–mesen-
chymal transition (EMT) suggests that metastatic cells arise
through a step-wise accumulation of gene mutations that
eventually transform an epithelial cell into a tumor cell with
mesenchymal features [1, 9, 18–21]. The idea for an EMT
origin comes from findings that many cancers generally
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and cell–matrix interactions occur during tumor progression
[22]. Eventually, neoplastic cells emerge that appear as
mesenchymal cells, which lack cell–cell adhesion and are
dysmorphic in shape [17]. These transformed epithelial
cells eventually acquire the multiple effector mechanisms of
metastasis [17]. Recent studies suggest that ectopic co-
expression of only two genes might beallthatisnecessaryto
facilitate EMT in some gliomas [23]. Considerable contro-
versy surrounds the EMT hypothesis of metastasis, as
evidence of EMT is not often detected in tumor pathological
preparations [22, 24, 25].
Based on numerous similarities between macrophages
and metastatic cancer cells, we propose that many meta-
static cancers arise from cells of the myeloid lineage. More
specifically, metastatic cells arise from resident or infiltrat-
ing macrophages or myeloid cells of the tumor stroma that
become neoplastic during disease progression. As mesen-
chymal cells [26, 27], myeloid/macrophage-type cells
would naturally embody to the capacity to express multiple
behaviors of metastasis. The basis for this hypothesis comes
from our recent findings from unique metastatic tumors that
arose spontaneously in the inbred VM mouse strain [14,
28]. Two of these highly metastatic/invasive tumors express
multiple properties of macrophages. It is unlikely that the
metastatic properties of these mouse tumors are unique, as a
review of the literature indicates that these mouse tumors
share multiple properties with most types of human
metastatic cancers. The similarities between the mouse
and human metastatic cancers raise the possibility that
metastasis is a disease of myeloid cells regardless of tissue
origin. Our goal is to highlight the similarities of myeloid
cells (especially macrophages) and metastatic cancer cells,
and to discuss the possible mechanisms by which these
cells could become neoplastic.
2 Linkage of macrophages with metastatic cancer
Macrophages have long been considered the origin of human
metastatic cancers; however, this has not been widely
accepted or recognized [12, 29–32]. Rather than being
considered part of the neoplastic cell population, macro-
phages are generally considered part of the tumor stroma as
macrophages form a large portion of the inflammatory cell
infiltrate in most cancer types [33, 34]. Depending on the
tumor type, tumor-associated macrophages (TAMs) can
constitute up to 80% of the total tumor mass [35]. TAMs
are known to facilitate tumor development and progression
by establishing a pre-metastatic niche and by enhancing
tumor inflammation and angiogenesis [33, 36–39].
Macrophages are among the most versatile cells of the
body with respect to their ability to migrate, to change
shape, and to secrete growth factors and cytokines [14, 40–
42]. Macrophages are known to have two distinct polariza-
tion states: the classically activated (or M1) and the
alternatively activated (or M2). Macrophages acquire the
M1 phenotype in response to pro-inflammatory molecules
and release inflammatory cytokines, reactive oxygen
species, and nitric oxide [34, 43–46]. In contrast, macro-
phages acquire the M2 phenotype in response to anti-
inflammatory molecules such as IL-4, IL-13, IL-10, and
apoptotic cells [43, 47]. Additionally, M2 macrophages are
poor antigen presenters, immunosuppressive, and promote
tissue remodeling and repair [34]. Emerging evidence
suggests that M1 and M2 macrophages have distinct roles
during tumor initiation and malignant progression [48].
M1 macrophages are believed to facilitate the early stages
of tumorigenesis through the creation of an inflammatory
microenvironment that produces DNA and mitochondrial
damage [48, 49]. However, after the establishment of the
primary tumor, during tumor progression, TAMs generally
undergo a phenotypic switch and acquire the M2 polariza-
tion state [43]. The M2 TAMs scavenge debris and promote
tumor growth, angiogenesis, and metastasis [34, 43, 44].
Increasing evidence suggests that myeloid/macrophage
cells are also part of the malignant cell population. Aichel
first proposed over a century ago that tumor progression
involved fusion between leukocytes and somatic cells
(reviewed in [31]). Several human metastatic cancers are
known to express multiple molecular and behavioral
characteristics of macrophages to include phagocytosis,
cell–cell fusion, and antigen expression (Table 1). We
suggest that an origin from myeloid cells can account for
many properties of metastatic cancer.
3 The wound-healing M2 macrophage
and the metastatic cell: behavioral similarities
Interestingly, macrophages express most hallmarks of
metastatic tumor cells when responding to tissue injury or
disease. For example, monocytes extravasate from the
vasculature and are recruited to the wound via cytokines
released from the damaged tissue. Within the wound,
monocytes differentiate into alternatively activated macro-
phages and dendritic cells where they release a variety of
pro-angiogenic molecules including vascular endothelial
growth factor, fibroblast growth factor, and platelet-derived
growth factor [126, 127]. M2 macrophages also actively
phagocytose dead cells and cellular debris [42, 128]. On
occasion, macrophages undergo homotypic fusion resulting
in multinucleated giant cells with increased phagocytic
capacity [29, 129]. Following these wound-healing activi-
ties, macrophages intravasate back into the circulation
where they travel to the lymph nodes to participate in the
696 Cancer Metastasis Rev (2010) 29:695–707immune response [42, 130, 131]. These findings indicate
that normal macrophages are capable of intravasation,
tissue invasion, release of pro-angiogenic molecules/cyto-
kines, survival in hypoxic and necrotic environments, and
extravasation, i.e., hallmark behaviors of metastatic tumor
cells.
4 Phagocytosis: a shared behavior of M2 macrophages
and metastatic cells
Phagocytosis, the engulfment and ingestion of extracellular
material, is a specialized behavior of M2 macrophages and
other professional phagocytes [42]. This process is essential
for maintaining tissue homeostasis by clearing apoptotic
cells, cellular debris, and invading pathogens [42]. Inter-
estingly, many malignant tumor cells are phagocytic both in
vitro and in vivo (Table 1). Macrophages also express high
levels of lysosomal-enriched cathepsins, which facilitate the
digestion of proteins ingested following phagocytosis or
pinocytosis [132, 133]. This is interesting since lysosomal
cathepsins D and B are viewed as prognostic factors in
cancer patients [133]. Indeed, a high content of these
enzymes in tumors of the head and neck, breast, brain,
colon, or endometrium was considered a sign for high
malignancy, high metastasis, and overall poor prognosis
[133].
The phagocytic behavior of tumor cells was first
described over a century ago from histopathological
observations of foreign cell bodies within in the cytoplasm
of cancer cells, which displayed crescent-shaped nuclei
[134]. This cellular phenotype, commonly referred to as
either “birds-eye” or “signet-ring”, is the result of the
ingested material pushing the nucleus to the periphery of
the phagocytic cell [116]. While this phagocytic/cannibal-
istic phenomenon is commonly seen in feeding micro-
organisms, cell cannibalism is an exclusive property of
malignant tumor cells in humans [116]. These tumor cell
phagocytic/cannibalistic behaviors are not to be confused
with autophagy, a cellular self-digestion process often
associated with starvation conditions [135, 136]. It has
been reported that both human and murine cancers can
phagocytose other tumor cells, erythrocytes, leukocytes,
platelets, dead cells, as well as extracellular particles
(Table 1)[ 56, 77, 116].
4.1 Phagocytic cancers
Numerous reports have described the phagocytic behaviors
seen in aggressive human cancers and in some murine
tumors (Table 1). We previously identified two spontaneous
invasive/metastatic murine brain tumors (VM-M2 and VM-
M3) that express many macrophage behaviors including
phagocytosis [14]. While extracranial metastasis of central
nervous system tumors is not common, many gliomas,
especially glioblastoma multiforme, are highly metastatic if
the tumor cells can gain access to extraneural sites [14,
137–141]. Moreover, extracranial metastasis portends an
Tumor Phagocytosis Fusogenicity Gene expression
Bladder [50]
Brain [14, 51–54][ 55][ 14, 54]
Breast [56–63][ 64–68][ 69–71]
Carcinoma of unknown primary [72][ 73]
Endometrial [74]
Fibrosarcoma [63]
Gall bladder [75]
Liver [76]
Lung [57, 77–80][ 67][ 81–84]
Lymphoma/leukemia [85–87][ 88–91]
Melanoma/skin [92–96][ 32, 97, 98][ 96, 99–101]
Meth A sarcoma [102][ 102][ 102]
Multiple myeloma [103][ 104]
Ovarian [63, 105][ 106]
Pancreatic [107, 108][ 109][ 108]
Rectal [110]
Renal [111][ 112, 113][ 111]
Rhabdomyosarcoma [114, 115]
Reviews [116–119][ 12, 15, 29–31, 89, 120–125]
Table 1 Tumors expressing
macrophage characteristics
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surviving less than 6 months from the diagnosis of
metastatic disease [142].
The phagocytic activity of the metastatic VM-M2 and
VM-M3 tumor cells was similar to that of the RAW 264.7
macrophage cell line [14]. Similar findings were reported
for the methylcholanthrene-induced murine P388 mouse
lymphoma cells, which display macrophage morphology,
form rosettes, phagocytose latex beads, and strongly adhere
to glass and plastic surfaces [85]. These findings indicate
that some mouse tumor cell lines can manifest the
phagocytic behavior seen in macrophages and in numerous
human metastatic cancers.
While phagocytic behaviors have been reported for most
forms of human cancer including skin, breast, lymphoma,
lung, brain, ovarian, pancreatic, renal, endometrial, rhab-
domyosarcoma, myeloma, fibrosarcoma, and bladder, not
all cancer cells within a tumor are phagocytes (Table 1). For
most of the tumors described, phagocytosis was restricted
primarily to those cells that are highly invasive and
metastatic [14, 51, 52, 56–58, 78, 79, 92, 93, 107]. Lugini
et al. measured the phagocytic behavior of cell lines derived
from primary human melanomas (n=8) and metastatic
lesions (n=11) [92]. Interestingly, the phagocytic behavior
all of the cell lines derived from metastatic lesions was
similar to that of the macrophage controls, whereas
phagocytic behavior was not found in any of the cell lines
derived from primary melanomas [92]. Histological exam-
ination of in vivo metastatic melanoma lesions confirmed
the presence of phagocytic tumor cells [93]. Similar
findings of phagocytosis were reported for human meta-
static breast cancer [56]. Numerous phagocytic tumor cells
were identified within metastatic breast cancer lesions and
were not observed within the primary tumor of the same
patient [56]. Additionally, breast cancer malignancy and
grade correlates with the number of phagocytic tumor cells
present within the tumor stroma [59].
4.2 Targeting phagocytosis
Several investigators suggested that tumor cell phagocyto-
sis could be targeted as a potential therapy for metastatic
cancers. For example, Ghoneum et al. showed that MCF-7
breast cancer cells undergo apoptosis after engulfing yeast
cells either in vitro or in vivo [58, 60]. Phagocytosis of
yeast cells also effectively induces apoptosis in human
cancers of the gastrointestinal tract including tongue,
squamous cell carcinoma, and colon adenocarcinoma
[143]. These reports suggest that the phagocytic behavior
of metastatic tumor cells can be targeted for the develop-
ment of new anti-metastasis therapies.
Additionally, the phagocytic activity of metastatic
melanoma cells is significantly increased when the cells
are grown under low glucose conditions suggesting that
metastatic cells use phagocytosis as a way to “feed” when
nutrient supplies are low [93, 94]. Therefore, a metastasis
targeted therapy could be effective if administered to
energy-stressed metastatic tumor cells. Dietary energy
restriction (DR) is an effective means to reduce circulating
glucose levels and induce energy stress in tumor cells. DR
can also reduce inflammation and tumor angiogenesis while
increasing tumor cell apoptosis [144–148]. Moreover, DR
increases macrophage phagocytosis [149]. Hence, DR
administered in combination with an anti-phagocytosis
targeted therapy could potentially reduce primary tumor
size, vascularity, and the number of metastatic tumor cells.
4.3 Phagocytosis for diagnostics
Effective resection of invasive/metastatic tumors can be
improved if the margins between tumor tissue and normal
tissue are readily identified. In order to identify rat C6
glioma cells that invaded beyond the main tumor mass,
Zimmer et al. used monocrystalline iron oxide nano-
particles that the tumor cells could phagocytose as a
contrasting agent [150]. This was able to identify gliomas
cells that had invaded into the rat parenchyma. Viewed
collectively, these studies suggest that the phagocytic
behavior of tumor cells can be exploited for therapeutic
strategies and development of new diagnostic/imaging
protocols.
5 Fusogenicity
Fusogenicity is the ability of a cell to fuse with another cell
through the merging of their plasma membranes [129]. This
process can be easily induced in vitro as is seen with the
formation of antibody-producing hybridomas. However,
cell fusion in humans is a highly regulated complex process
that is essential for fertilization (sperm and egg), and
skeletal muscle (myoblasts) and placenta (trophoblast)
formation. Outside of these developmental processes, cell-
to-cell fusion is normally restricted to differentiated cells of
myeloid origin (reviewed in [120]). During differentiation,
subsets of macrophages fuse with each other to form
multinucleated osteoclasts in bone or multinucleated giant
cells in response to foreign bodies [29]. Osteoclasts and
giant cells have increased cell volume that facilitates
engulfment of large extracellular materials [29]. Macro-
phages are also thought to fuse with damaged somatic cells
during the process of tissue repair [29, 129, 151, 152].
In addition to homotypic fusion, macrophages are known
to undergo heterotypic fusion with tumor cells [29, 30, 120,
153]. Aichel first suggested in 1911 that fusion between
somatic cells and leukocytes could induce aneuploidy
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[32]). Nearly 60 years later, Mekler and Warner proposed
that fusion of committed tumor cells with host myeloid
cells would produce tumor hybrids capable of migrating
throughout the body and invading distant organs [121,
154]. Recently, this hypothesis has received more attention
with the findings reported by John Pawelek and colleagues
[30, 31, 69, 97, 98, 112, 113, 155]. They also suggested
that these hybrids could account for the diversity of cell
phenotypes within tumors [121, 154]. Fusion between
tumor cells and myeloid cells, with subsequent nuclear
fusion, could produce new phenotypes in the absence of
new mutations, as the hybrids would express genetic and
functional traits of both parental cells [32]. These neoplastic
hybrids would have the ability of macrophages to intra-
vasate, to extravasate, and to migrate to distant organs
while also possessing the unlimited proliferative potential
of the cancer cells. Since myeloid cells are part of the
immune system, tumor hybrids would also be able to evade
immune surveillance [25].
5.1 Fusogenic cancers
Fusogenic tumor cells are found in a wide variety of cancer
types including, melanoma, breast, renal, liver, gall bladder,
lymphoma, and brain (Table 1). Tumor cell hybrids can
form either in vitro or in vivo from fusions between two
tumor cells or between a tumor cell and a normal somatic
cell. One of the first reports of tumor cell fusion hybrids
showed that human glioma cells, when implanted within
the cheeks of hamsters, spontaneously fused with non-
tumorigenic host cells, resulting in metastatic hybrid
human-hamster tumor cells [55]. Many of the early reports
for fusogenic cancers described fusions between lympho-
mas and myeloid cells. For example, spontaneous in vivo
fusion between the non-metastatic murine MDW4 lymphoma
and host bone marrow cells resulted in aneuploid metastatic
tumor cells [88].
Munzarova et al. recognized that numerous traits
expressed in macrophages were also expressed in metastatic
melanoma cells and suggested that the tumor metastasis
could result from fusions between tumor cells and macro-
phages [12, 122]. Rachkovsky et al. tested this hypothesis
by inducing fusions between cultured non-metastatic
Cloudman S91 melanoma cells and murine peritoneal
macrophages. The majority of the resulting macrophage-
melanoma hybrids displayed increased metastatic potential
when grown in vivo [32]. Further studies revealed that the
Cloudman S91 melanoma cells could undergo spontaneous
fusion with the murine host cells in vivo resulting in
secondary lesions that were comprised mostly of tumor-
host cell hybrids. The authors concluded that the tumor
cells likely fused with host myeloid cells [97]. Artificial
fusions of human monocytes and mouse melanoma cells
revealed that the resulting hybrids expressed both human
and mouse genes [98]. Other investigators also showed that
the macrophage-specific antigens F4/80 and Mac-1 were
expressed in murine Meth A sarcoma cells after spontaneous
in vivo fusion with host cells. Interestingly, latex bead
phagocytosis was also expressed in the Meth A sarcoma-host
cell fusion hybrids [102]. Since these fusion hybrids
expressed genotypes and phenotypes of both parental cells,
it appears that the non-metastatic tumor cells could acquire
an invasive/metastatic phenotype without new mutations.
Fusion among tumor cells in human solid tumors is
difficult to detect. Recent reports, however, have provided
direct evidence for fusions between tumor cells and
myeloid cells in human bone marrow transplant (BMT)
recipients [112, 113]. Both radiation therapy and immuno-
suppression can increase the incidence of metastatic cancers
[156]. DNA analysis of micro-dissected metastatic cells
from a child diagnosed with renal cell carcinoma after a
BMT revealed DNA from both the BMT donor and the
recipient in the metastatic cells [112]. Bone marrow and
tumor cell hybrids were also identified in a female who
developed renal carcinoma after receiving a BMT from a
male donor [113]. These reports provided the first genetic
evidence that spontaneous fusions can occur between
human myeloid cells and tumor cells.
It is well documented that tumor-associated macro-
phages promote tumor progression in many cancers through
the release of cytokines, and pro-angiogenic and pro-
metastatic molecules (reviewed in [33, 38]). However, the
fusion of cancer cells with tissue macrophages could also
accelerate tumor progression. The tumor hybrid daughter
cells could acquire the migratory/invasive behavior from
the macrophage genome while still maintaining unlimited
proliferative potential. Macrophage-macrophage fusions
could also induce aneuploidy resulting in a tumorigenic
myeloid cell [30, 123]. The significance of macrophage
fusion hybrids in human metastatic cancer requires more
attention. The numerous in vitro studies and in vivo reports
suggest that myeloid hybrids are responsible for the
metastatic progression of at least a subset of cancers.
Multinucleated giant cells, a signature of hybrid formation,
are frequently seen in human cancers, suggesting that cell
fusions are not rare events (Table 1). Regardless of the
mechanism, metastatic cells express numerous behaviors of
mesenchymal/myeloid cells and, if exploited, could generate
novel therapeutic strategies for managing metastatic cancers.
6 Tumor cell expression of myeloid antigens
Myeloid cells express a wide variety of markers that are
unique to their ontogeny and function [157]. Routine
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preformed to assess tumor type and grade. Since TAMs are
often correlated with a poor patient prognosis, tumor
biopsies are frequently evaluated for macrophage markers.
The macrophage antigen-expressing cells within the tumor
stroma are usually classified as TAMs. However, several
reports show that macrophage-specific antigens are
expressed on a wide variety of human cancer cells (Table 1).
Ruff and Pert demonstrated that several macrophage
antigens (CD26, C3bi, and CD11b) were expressed on
tumor cells from small cell lung carcinoma (SCLC) [81].
Levels of expression were comparable to that seen in the
monocyte controls. It is important to note that the
macrophage antigens were expressed in the cultured tumor
cells themselves and further confirmed in vivo.T h i s
eliminated the possibility that the antigen expression was
derived from TAMs. These investigators concluded that the
SCLC tumor cells in their specimens were not of lung
origin, but rather were of myeloid origin. A malignant
transformation of recruited myeloid cells, from smoking-
related tissue damage, was offered as an explanation for the
origin of tumor cells with myeloid/macrophage properties
[81]. Although this interpretation was controversial [70,
82], the authors demonstrated additional myeloid properties
of these tumor cells [83]. Other investigators confirmed
macrophage antigen expression on other SCLC tumors and
cell lines [82, 84]. Myeloid-associated antigens (CD14 and
CD11b) were also expressed in five metastatic breast cancer
cell lines [70]. None of the breast cancer cell lines,
however, expressed markers for B or T cells [70]. The
authors suggested that common antigen sharing between
different cell types could be related to common cellular
interactions [70]. In light of these findings and those from
Ruff and Pert, we suggest that the shared antigen
expression of macrophages and metastatic tumor cells is
the result of a common mesenchyme origin.
Further evidence for a mesenchymal origin of metastatic
cancer comes from tissue microarray analysis of 127 breast
cancer patients [71]. CD163 was expressed on the tumor
cells of 48% of the patients, while MAC387 was expressed
on the tumor cells of 14% of the patients [71]. Pathology
confirmed that the staining was localized to the tumor cells
and not solely to the tumor infiltrating macrophages.
Interestingly, cancers that contained CD163-expressing
tumor cells had a more advanced histological grade, a
higher occurrence of distant metastasis, and reduced patient
survival [71]. This report demonstrated, for the first time,
that tumor cells expressing macrophage antigens could be
identified in more than half of breast cancer patients.
Similar studies were conducted on 163 patients with rectal
cancer [110]. CD163 was expressed in 31% of the rectal
tumors from patients in the preoperative irradiation group,
but in only 17% in the non-irradiation group. Prognosis was
also worse for those patients with CD163-positive cancer
cells than in those patients with CD163-negative cancer
cells [110]. These findings are consistent with role of
radiation in inducing tumor cell–macrophage fusions and in
exacerbating the metastatic properties of some cancers [71,
110, 158]. These studies demonstrated that macrophage
antigens, which are associated with enhanced metastasis
and poor prognosis, are expressed on the tumor cells of
patients with breast and rectal cancers.
7 Carcinoma of unknown primary origin
Carcinoma of unknown primary (CUP) is a systemic
metastatic disease without an identifiable primary tumor
and is often associated with poor prognosis. Approximately
5% of all newly diagnosed cancers are classified as CUP
[159, 160]. Histologically,these cancers are usuallyclassified
as adenocarcinomas, squamous cell carcinomas, poorly
differentiated carcinoma, and neuro-endocrine carcinomas
[160]. It is thought that these aggressive cancers rapidly
metastasize before the primary tumor has had time to
develop into a macroscopic lesion [160]. Interestingly,
aneuploidy was identified in 70% of CUP adenocarcinoma,
suggesting that these cancers contain hybrid cells [29, 73].
Reports have also demonstrated that CUP contain signet-ring
cells, indicating that a subset of these cancers exhibit
phagocytic behavior [72]. Due to the highly aggressive
nature of these tumors, we suggest that some CUPs could
have a myeloid/macrophage origin.
8 Many cancers express multiple macrophage properties
The evidence presented in this review indicates that many
metastatic cancers can express multiple myeloid character-
istics (Table 1). For instance, many tumors that were
phagocytic or fusogenic also expressed myeloid antigens,
further supporting a myeloid origin of these metastatic
cancers. It is important to note that the myeloid properties
we highlighted were expressed in the tumor cells themselves
and should not be confused with myeloid properties
expressed by tumor-associated macrophages, which are also
present in the tumors but are not tumorigenic.
9 Possible mechanisms
Emerging evidence indicates that cancer is a metabolic
disease, regardless of tissue or cellular origin, which arises
as a result of impaired cellular energy metabolism and
700 Cancer Metastasis Rev (2010) 29:695–707mitochondrial dysfunction (reviewed by [22]). Numerous
studies indicate that tumor mitochondria are abnormal and
are incapable of generating normal levels of energy [49,
161–166]. Defective mitochondria often arise as the result
of damage to mitochondrial membrane lipids, specifically
cardiolipin, through mutagens/carcinogens, radiation, hyp-
oxia, inflammation, reactive oxygen species, and inherited
mutations that alter mitochondrial energy production [49].
It is currently believed that any impairment in mitochon-
drial energy formation can lead to genetic instability via the
retrograde (RTG) response, a signaling pathway that
consists of sensors such as HIF-1α and NfkB that detect
mitochondrial stability [167]. Activation of the RTG
pathway results in the synthesis of ATP through glycolysis
when respiratory function is impaired. Over time, this
respiration impairment would result in the upregulation of
the TCA cycle and glycolytic substrate level phosphoryla-
tion, and induce proliferation and genetic defects, resulting
in malignant transformation [22, 167–169]. These findings
indicate that the integrity of the nuclear genome is
dependent upon the functionality of the mitrochondria for
all cell types, including cells of myeloid and macrophage
origin [22].
Metastatic myeloid tumor cells could arise from resident
tissue macrophages or TAM that have suffered mitochondria
damage(Fig.1). The majority of tissues contain macrophages
as part of their normal cellular composition and TAM are also
a major cell type in most cancers where they can facilitate
tumor progression [33, 42, 157, 158]. In fact, depending on
the tumor type, as noted above, up to 80% of the cells within
a tumor are macrophages [33, 35]. Macrophages generally
hone to mitochondria-damaging environments in response to
inflammation, infection, would repair, and tumorigenesis [37,
38, 126, 128, 170]. It seems likely that mitochondria damage
would occur resulting in cellular transformation through the
RTG response where glucose and glutamine become the
primary metabolic fuels for growth and survival [158, 171].
Glucose and glutamine are also major energy metabolites for
normal cells of myeloid/macrophage lineage [158, 172].
Damage to myeloid/macrophage respiratory function could
lead to a reliance on substrate level phosphorylation for
energy, resulting in a malignant macrophage with the highest
metastatic potential [22].
Mitochondria are dynamic organelles that undergo regular
fusion and fissions [173]; thus, abnormalities in mitochon-
drial lipid composition would be rapidly disseminated
throughout the cell’s mitochondrial network and could also
be passed along to other cells through cytoplasmic
inheritance during cellular fusion events. While cell fusion
events are considered rare outside of normal developmental
processes, various reports have demonstrated that the
frequency of cell fusion can be up to 1% in in vivo tumor
models [64, 120, 123]. Additionally, chronic inflammation
increases fusion events [174, 175]. Considering the large
number of cells within a solid tumor, the fusogenic cell
population could comprise a significant portion of the tumor.
Mitochondrial
Damage
Metastatic 
Macrophage
RTG
A
B
Inflammation
Radiation
Hypoxia
Mutagens
ROS
macrophage X
tumor genome
TAM
Tumor cell
Damaged
mitochondria
Virus
Fig. 1 Proposed mechanisms of
macrophage transformation. The
tumor microenvironment
consists of numerous
mitochondria-damaging
elements which would likely
result in impaired mitochondria
energy production in TAM and
tissue macrophages and
subsequent genetic instability
through the RTG response (A).
Macrophage fusion hybrids
could result in cells able to
express both the tumor and
macrophage genomes resulting
in cells with metastatic
potential (B)
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cytoplasms [120, 129, 176]. Therefore, the formation of
cancer cell and macrophage fusion hybrids would result in
the transfer of damaged mitochondria from the cancer cell to
the macrophage hybrid daughter cells. The subsequent
inheritance of abnormal mitochondria would likely result in
the transformation of the hybrid genome through the RTG
response [22, 167–169]. In fact, the presence of fusion
hybrids has been shown to correlate with tumor malignancy
[65].
While it is unknown what triggers formation of
macrophage × tumor hybrids, various steps in the macro-
phage response to tumor development could provide the
opportunity for cell fusion. Within hypoxic tumor areas,
macrophages digest apoptotic cells. It has been suggested
that macrophages may abort cellular digestion resulting in
hybrid formation [31]. Additionally, macrophages could
also fuse with somatic cells during tissue repair. Since
tumors represent unhealed wounds [33, 177], it is possible
that macrophages could fuse with tumor cells in an attempt
to “heal” the tissue. Radiation damage during therapeutic
intervention will also enhance fusion leading to more
aggressive and difficult to manage tumors [110, 158].
Fusion events could also arise through the action of tumor-
associated viruses, as several different tumor types (leukemia,
lymphoma, Kaposi sarcoma, hepatocellular carcinoma,
anogenital cancers, etc.) are associated with viral infection
[124, 153]. Viral proteins enable successful cellular infection
by fusing biological membranes. Additionally, some viruses
utilize cellular fusion as a way to facilitate their spread
(reviewed in [124]). Interestingly, several tumor-associated
viruses including Epstein–Barr virus, Kaposi’ss a r c o m a -
associated herpes virus, human papilloma virus (HPV),
hepatitis B and C viruses, Rous sarcoma virus, and human
T cell leukemia virus type 1 localize to the mitochondria
compartment of the cell where they could potentially cause
mitochondria defects [178–181].
The macrophage fusion hypothesis is an attractive
explanation for metastasis. Fusions among macrophages
and tumor cells could also account for histological
structures in metastatic sites that resemble the histology of
the primary tumor tissue as it has been shown, through
reprogramming strategies, that macrophages are capable of
producing fully functional epithelial cells at secondary sites
while retaining histological characteristics of the original
primary tissue [123, 182, 183]. Tumor fusions could also
explain aneuploidy and chromosomal abnormalities seen in
most cancer cells [31, 124]. However, there are conflicting
observations showing suppressed tumorigenicity following
hybridization between normal cells and tumor cells [22, 184].
Damage to the respiratory capacity of resident tissue
phagocytes, TAM, or macrophage hybrids would trigger
a RTG response and over time lead to uncontrolled
proliferation and genomic instability. Metastatic behavior
would be the expected outcome of impaired mitochon-
drial function in myeloid or macrophage cells, as these
cell types are mesenchymal cells that are able to degrade
the extracellular matrix, migrate through local tissues,
and enter and exit the circulation.
10 Modeling the myeloid origin of metastasis
The development of more effective therapies for the
management of human metastatic cancers can be improved
with animal models that accurately reflect the human
disease. We recently described two new mouse models of
systemic metastatic cancer in the inbred VM mouse strain
that express multiple myeloid/macrophages characteristics
to include phagocytosis, morphological appearance, and
gene and lipid expression [14, 28, 185]. The VM-M2 and
the VM-M3 tumors model all major steps of metastasis
including, local invasion, intravasation, immune system
survival, extravasation, and secondary tumor formation [14,
28, 185]. Moreover, the VM-M2 and the VM-M3 tumor
cells are naturally metastatic from any inoculated tissue
and, in contrast to most other mouse metastatic models, do
not require intravenous injections to initiate the metastatic
phenotype. Tumor cells that possess true or natural
metastatic potential should not require intravenous injection
to demonstrate metastasis. We also showed that the
response of the metastatic VM tumors to well described
anti-cancer drugs (cisplatin and methotrexate) was similar
to that described previously in human cancer patients
treated with these drugs [28]. We suggest that these
mouse models of systemic metastatic cancer will be useful
for developing novel therapies that target the myeloid
properties of metastasis.
11 Concluding remarks
A transition from an epithelial-type cell to a mesenchymal-
type cell is often considered an underlying characteristic of
metastasis. As an alternative to a series of gain-of-function
mutation events, we suggest that the metastatic mesenchymal
phenotype can arise from malignant myeloid cells either
throughcellhybridformationorthroughdirecttransformation
of tissue macrophages. We think that it is improbable that
random mutations acquired through a Darwinian selection
process could account for all of the myeloid-cell behaviors
necessary for the completion of the metastatic cascade. It is in
our opinion that the myeloid origin of metastasis is the most
probable explanation of tumor progression to date.
702 Cancer Metastasis Rev (2010) 29:695–707We suggest that future research in this field should focus
on the myeloid properties of metastatic cells. The VM
mouse model, as well as many of the human and murine
cell lines discussed above, will be valuable for the
development of novel metastasis therapies. Additionally,
we urge others to consider the possibility that some of the
cells previously identified as TAM in tumor pathological
tissue specimens may in fact be metastatic tumor cells. This
is especially true since TAMs are often localized to the
leading edge of an invading tumor mass, and high levels of
TAM are usually indicative of poor prognosis. We contend
that targeting macrophage behaviors (e.g., phagocytosis,
fusogenicity, and energy metabolism) would result in
therapies that are effective in managing metastatic cancer,
regardless of primary tumor origin.
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